Tag Archive for: CAR-T

Radioligand Therapy Plus CAR‑T: A New Strategy to Reprogram the Prostate Cancer Microenvironment

/in , /by

A new preclinical study shows that radioligand therapy (RLT) can directly enhance CAR‑T cell efficacy in metastatic castration-resistant prostate cancer (mCRPC), addressing two major barriers: antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Researchers combined 177Lu‑PSMA‑617 (Pluvicto) with PSCA-targeted CAR‑T cells in sequence (RLT → cyclophosphamide → CAR‑T). Compared to either treatment alone, the combination […]

Read more

A PSMA‑Targeted CAR‑T Cell Therapy with CD16A Signaling for Prostate Cancer

/in , /by

Adoptive transfer of chimeric antigen receptor (CAR) T cells has worked well in some blood cancers, but it has been much less effective in solid tumors like prostate cancer. One reason is the strong cytokine release and strong immune suppression in the tumor area. A new study has designed a PSMA‑targeted CAR that uses CD16A, […]

Read more

A New CAR‑T Strategy for Bone Cancer That May Help Metastatic Prostate Disease

/in , /by

Scientists have developed a promising new CAR‑T cell therapy for osteosarcoma, the most common bone cancer in children, adolescents, and young adults, and the work carries a cautiously optimistic signal for other solid tumors, including metastatic prostate cancer. In a preclinical study, researchers at Case Western Reserve University and University Hospitals engineered T cells to […]

Read more

P‑PSMA‑101 CAR‑T Therapy in Advanced Prostate Cancer: Early Results from a Phase 1 Trial

/in , , /by

P‑PSMA‑101 is an experimental CAR‑T cell therapy being tested in men with metastatic castration‑resistant prostate cancer (mCRPC) who have already received multiple standard treatments (up to 10 before enrollment). In the phase 1 trial, 33 men with heavily pretreated mCRPC received P‑PSMA‑101, an autologous PSMA‑targeted CAR‑T product enriched in stem‑cell‑like memory T cells and engineered […]

Read more

A-CAR032: a STEAP2-Targeted Armored CAR-T Enters First-in-Human Trial for Advanced Prostate Cancer

/in , , /by

A new Phase 1 clinical trial is testing A-CAR032, a CAR-T cell therapy, in patients with metastatic castration-resistant prostate cancer, or mCRPC. This first-in-human study targets STEAP2, a protein found on nearly all prostate cancer cells, including those that have spread to bones and lymph nodes. Prostate cancer creates a tough environment for immune cells […]

Read more

Phase 1 Trial: STEAP1 CAR‑T Plus Enzalutamide A New Immune Approach for mCRPC

/in , , , /by

STEAP1 is a protein that sits on the surface of many prostate cancer cells, especially in advanced metastatic disease. Because it is abundant on cancer cells and much less present in normal tissues, STEAP1 looks like a promising “flag” that engineered immune cells can use to distinguish tumor from healthy organs. ​ The treatment being […]

Read more

ADI-212: Immune Cells Engineered to Beat Advanced Prostate Cancer

/in , /by

ADI-212 is a new type of immune cell therapy made from gamma delta T cells, the kind of immune cells that naturally go after tumors. These cells are specially engineered to attack PSMA-positive metastatic castration-resistant prostate cancer. The therapy has two smart upgrades. First, it carries a special version of IL-12, a powerful immune signal, […]

Read more

UPDATE: AB-3028 Reaches Clinical Trial Stage for mCRPC

/in , , , /by

AB-3028, programmable circuit T cell therapy for metastatic castration-resistant prostate cancer (mCRPC), has now advanced into a Phase 1/2 clinical trial. This marks the first clinical testing of this highly engineered, logic‑gated CAR-T platform in prostate cancer, moving it from a purely preclinical concept into human evaluation. The trial should start recruiting in January 2026. […]

Read more

AB‑3028, a Dual‑antigen AND‑gated, TGF‑β–resistant CAR T Therapy

/in , /by

AB-3028 represents a next-generation approach to solid-tumor CAR T therapy tailored to the unique challenges of metastatic castration-resistant prostate cancer. CAR T cells, transformative in hematologic malignancies, have struggled in solid tumors due to heterogeneous antigen expression, on-target off-tumor risks, suppressive cytokines like TGF-β, and chronic stimulation that drives exhaustion. AB-3028 was engineered to counter […]

Read more

The Promise of In Vivo CAR T Cell Therapies

/in /by
Read more